恶唑酮
医学
生长速度
身材矮小
青春期延迟
生长激素
社会心理的
儿科
睾酮(贴片)
车身高度
特发性矮身高
内科学
内分泌学
激素
体重
精神科
作者
A Ferrández Longás,E Mayayo,Alfonso Del Valle,J Soria,Ignacio Díez López
出处
期刊:PubMed
[National Institutes of Health]
日期:1996-06-01
卷期号:9 Suppl 3: 345-57
被引量:15
摘要
Constitutional delay in growth and puberty (CDGP) is one of the principal causes of consultation due to short height. Frequently familial short stature is associated with the CDGP. The predicted final height is reached in the majority of the cases but some individuals do not achieve their target height. Poor growth, especially during the pubertal years, as well as a short or growth delayed mother are some of the negative factors for final outcome. Some prepubertal children show a transient diminished GH secretion that normalizes during puberty. Therapy with hGH or oxandrolone increases growth velocity but does not ameliorate final height. The psychosocial situation of the children is the most important condition to treat with testosterone, estrogens or oxandrolone. In view of the results hGH should not be administered routinely to these cases. It remains open which children could benefit from hGH therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI